We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Merck, Sysmex Collaborate To Develop And Commercialize Blood-Based RAS Biomarker Test
News

Merck, Sysmex Collaborate To Develop And Commercialize Blood-Based RAS Biomarker Test

Merck, Sysmex Collaborate To Develop And Commercialize Blood-Based RAS Biomarker Test
News

Merck, Sysmex Collaborate To Develop And Commercialize Blood-Based RAS Biomarker Test

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Merck, Sysmex Collaborate To Develop And Commercialize Blood-Based RAS Biomarker Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

“We are looking forward to this important collaboration with Merck Serono and to bringing our innovative technology to mCRC patients,” said Fernando Andreu, CEO of Sysmex Inostics. “Together, with our non-invasive, blood-based diagnostics and Merck’s expertise in personalized medicine, we will open up new possibilities to advance biomarker testing in mCRC.  This collaboration is another major step in enhancing the clinical value of Sysmex Inostics’ OncoBEAM™ tests and exemplifies Sysmex’s overall strategy to bring sensitive blood-based testing to the oncology field.”

Under the terms of the agreement, Sysmex Inostics will develop blood-based RAS diagnostic tests based on its BEAMing technology for patients with metastatic colorectal cancer. Sysmex Inostics’ BEAMing tests enable a very sensitive analysis of circulating tumor DNA shed into the blood stream. These tests provide a non-invasive alternative to traditional biopsies in determining the mutational status of a patient’s tumor. These blood-based biomarker tests allow for the selection of an appropriate therapeutic agent without the need for further surgeries or biopsies. Moreover, blood-based diagnostic DNA tests can be performed on patients where no tumor tissue is available.

“We are delighted to announce our strategic partnership with Sysmex Inostics,” said Belén Garijo, President and CEO of Merck Serono. “As a company, we have embraced the principles of personalized medicine and predictive biomarkers. This collaboration reflects our commitment to leveraging our expertise in personalized medicine and predictive biomarkers in order to enhance Erbitux’s value proposition for patients, physicians and payers.”

Advertisement